Ludwig Institute for Cancer Research Limited

Ludwig Institute

Etienne De Plaen

Thierry R Boon-Falleur

Catia Traversari

Aline Van Pel

Pierre Van Der Bruggen

Vincent Brichard

Benoit Van Den Eynde

Christophe Lurquin

Thierry Boon

Pierre G Coulie

Thomas Wolfel

Patrick Chomez

Beatrice Gaugler

Jean-Christope Renauld

Francis Brasseur

Bernard Lethe

Thomas W&ouml;lfel

Christophe Lurguin

Lan-Qing Huang

Charles De Smet

Pedro Romero

Donata Rimoldi

Jean-Pierre Szikora

Bernard Leth&eacute;

Christoph Lurquin

Thomas W Olfel

Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.

Tumour rejection antigens

The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.

Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3

Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.

Tumor rejection antigens

Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor

The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS

The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Method for treating cancer by administering MAGE-derived peptides

The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules

The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.

Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals

The invention involves nonapeptides bound by HLA molecules such as HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Isolated nonapeptides presented by HLA molecules, and uses thereof

A correlation between expression of tumor rejection antigen precursor MAGE-10 and cancer has been discovered. The invention is a method for determining presence of cancer in a sample by determining expression of MAGE-10. This determination can be made via, e.g., an immunoassay, an oligonucleotide hybridization assay, or via other standard methodologies.

Method for determining cancer by determining expression of MAGE-10

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or 'TRAP&rdquo;, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors

Isolated nonapeptides which bind to HLA molecules and provoke lysis by

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP', is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Precursor processed to at least one tumor rejection antigen presented by

Tumor rejection antigen precursors, tumor rejection antigens and uses

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or 'TRAP', is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Growing community of inventors

Brussels, Belgium

Etienne De Plaen